Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

The stock's fall snapped a two-day winning streak.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Gilead Sciences’ (NASDAQ: GILD) Q2 earnings are scheduled to be released on August 7, after market close. The pharma company ...

Magrolimab triple therapy falls short of expectations in a study of previously untreated acute myeloid leukemia.

The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's rob ...

Patients with HIV had lower adherence to pre-exposure prophylaxis (PrEP) if they lived in areas with the lowest disadvantage.

Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.

Portfolio Receipts was $727 million in the second quarter of 2025, an increase of 20% compared to $608 million in the second quarter of 2024, primarily driven by the same Royalty Receipts increases ...

Orchestrate agents autonomously with A2A: Aisera Unify natively supports A2A protocol, enabling real-time coordination across AI agents. Agents are discovered via dynamic Agent Cards backed by the ...

Total revenue for the three months ended June 30, 2025 increased by $1.5 million as compared to the three months ended June 30, 2024, primarily as a result of increases in Incyte revenue of $1.5 ...